SCHEMBL24577250

SCHEMBL24577250

Cc1cc(C(=O)NCCN2CCC(O)CC2)sc1NC(=O)c1cnn2cc(-c3cnn(C)c3)sc12

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NTRK1 P04629 2/20 0.37
▸ JAK2 O60674 1/20 0.37
▸ GSK3B P49841 3/20 0.36
▸ DYRK1A Q13627 3/20 0.36
▸ WNT1 P04628 2/20 0.36
▸ IRAK4 Q9NWZ3 1/20 0.35
▸ CHRM1 P11229 1/20 0.34
▸ PDGFRA P16234 1/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ MARK3 P27448 4/20 0.33
▸ STAT3 P40763 4/20 0.33
▸ KIT P10721 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ HPGD P15428 2/20 0.33
▸ PIK3CD O00329 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24577940 0.95 CHRM1 (0.35) NTRK1JAK2GSK3BDYRK1AWNT1
SCHEMBL24578949 0.95 CHRM1 (0.35) NTRK1JAK2GSK3BDYRK1AWNT1
SCHEMBL24577243 0.95 CHRM1 (0.35) NTRK1JAK2GSK3BDYRK1AWNT1
SCHEMBL24577938 0.92 CHRM1 (0.34) GSK3BDYRK1AWNT1IRAK4CHRM1
SCHEMBL24577246 0.92 KIT (0.40) CHRM1PDGFRAHRH3MARK3STAT3
SCHEMBL24577253 0.91 ACKR3 (0.39) JAK2CHRM1PDGFRAHRH3MARK3
SCHEMBL24577196 0.91 CHRM1 (0.36) NTRK1JAK2IRAK4CHRM1PDGFRA
SCHEMBL24578906 0.89 CHRM1 (0.39) NTRK1JAK2GSK3BDYRK1AIRAK4
SCHEMBL24577851 0.88 CHRM1 (0.38) GSK3BDYRK1AWNT1CHRM1PDGFRA
SCHEMBL24578970 0.87 CHRM1 (0.38) NTRK1JAK2GSK3BDYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2024-04-04 — — US disclosed
EP-4267585-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS Actelion Pharmaceuticals Ltd (CH) 2023-11-01 — — EP disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed
WO-2022136509-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2022-06-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109917-A1 PYRAZOLOTHIAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS PDGFRA, PDGFRB, ABL1 NTRK1 127/4885JAK2 9/4885GSK3B 1914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback